Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994596 | 1.00 | AKR1C1 (0.48) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL10659448 | 1.00 | AKR1C1 (0.48) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| Hydrochloric Acid SCHEMBL8114401 | 0.98 | AKR1C1 (0.47) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| Hydrochloric Acid SCHEMBL8114403 | 0.98 | AKR1C1 (0.47) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL16057460 | 0.95 | AKR1C1 (0.52) | AKR1C1HDAC4HSD11B1LMNAHTT | |
| SCHEMBL11241224 | 0.90 | AKR1C1 (0.40) | AKR1C1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11247968 | 0.89 | AKR1C1 (0.39) | AKR1C1 | |
| SCHEMBL11241214 | 0.86 | MMP2 (0.40) | AKR1C1 | |
| SCHEMBL11231091 | 0.86 | PLA2G10 (0.39) | AKR1C1HSD11B1LMNA | |
| SCHEMBL11234892 | 0.86 | ALDH1A1 (0.39) | AKR1C1HDAC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037645-B2 | Methods of detecting cancer | IMMUNIS.AI, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4381091-A2 | COMPOSITIONS AND METHODS FOR DETECTING PROSTATE CANCER | Immunis.AI, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4075139-B1 | METHODS OF DETECTING PROSTATE CANCER | IMMUNIS AI INC (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158863-A1 | METHODS OF DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240018501-A1 | HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVAL | UNIV ILLINOIS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4303584-A2 | METHODS FOR DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS | President and Fellows of Harvard College (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230280346-A1 | METHODS OF DETECTING PROSTATE CANCER | IMMUNIS.AI, INC. | 2023-09-07 | — | — | US | disclosed |
| EP-4202441-A2 | GENE EXPRESSION PROFILE IN MACROPHAGES FOR THE DIAGNOSIS OF CANCER | Immunis.AI, Inc. (US) | 2023-06-28 | — | — | EP | disclosed |
| WO-2011012810-A1 | 2-AMINO-2-PHENYL-ALKANOL DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | OROXCELL (FR) | 2011-02-03 | — | — | WO | disclosed |
| EP-2240781-A1 | METHODS OF DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS | President and Fellows of Harvard College (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010117525-A1 | METHOD OF MAKING RIBOSOMES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-101842098-A | Nitrogen-containing bicyclic chemical entities for the treatment of viral infections | GENELABS TECH INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009092068-A1 | METHODS OF DETECTING SIGNATURES OF DISEASE OR CONDITIONS IN BODILY FLUIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7311893-B2 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | AKR1C1 4316/4885HDAC4 3512/4885HSD11B1 2229/4885 |
| US-20050048000-A1 | Amyloid targeting imaging agents and uses thereof | APP, APBA1, BACE1 | AKR1C1 2817/4885HDAC4 4381/4885HSD11B1 3882/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | AKR1C1 2391/4885HDAC4 1478/4885HSD11B1 2958/4885 |
| US-20240018501-A1 | HIGHER PERFORMANCE PROTEASES FOR SCARLESS PEPTIDE TAG REMOVAL | LNPEP, RNPEP, ANPEP | AKR1C1 4552/4885HDAC4 4446/4885HSD11B1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.